{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:51:12Z","timestamp":1791442272013,"version":"4.3.3"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Journal Armed Forces India"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.mjafi.2020.08.004","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T07:53:16Z","timestamp":1599033196000},"page":"370-376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":331,"title":["Favipiravir: A new and emerging antiviral option in COVID-19"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2105-3932","authenticated-orcid":false,"given":"Umang","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3335-6698","authenticated-orcid":false,"given":"Reyma","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1830-3259","authenticated-orcid":false,"given":"Zarir F.","family":"Udwadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mjafi.2020.08.004_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir Res"},{"key":"10.1016\/j.mjafi.2020.08.004_bib3","unstructured":"Toyama Chemicals. Summary of Product Characteristics of Avigan."},{"key":"10.1016\/j.mjafi.2020.08.004_bib4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40262-015-0364-1","article-title":"Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials","volume":"55","author":"Madelain","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.mjafi.2020.08.004_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068347","article-title":"The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5\u2032-triphosphate towards influenza A virus polymerase","volume":"8","author":"Jin","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.mjafi.2020.08.004_bib6","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in\u00a0vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.mjafi.2020.08.004_bib7","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1128\/AAC.01739-09","article-title":"In\u00a0vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses","volume":"54","author":"Sleeman","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mjafi.2020.08.004_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antivir Res"},{"key":"10.1016\/j.mjafi.2020.08.004_bib9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"Smither","year":"2014","journal-title":"Antivir Res"},{"key":"10.1016\/j.mjafi.2020.08.004_bib10","article-title":"Experimental treatment with favipiravir for ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.mjafi.2020.08.004_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/infdis\/jiz078","article-title":"Laboratory findings, compassionate use of favipiravir, and outcome in patients with ebola virus disease, Guinea, 2015-A retrospective observational study","volume":"220","author":"Kerber","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mjafi.2020.08.004_bib12","series-title":"Favipiravir Strikes the SARS-CoV-2 at its Achilles Heel, the RNA Polymerase","author":"Shannon","year":"2020"},{"key":"10.1016\/j.mjafi.2020.08.004_bib13","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In\u00a0vitro and in\u00a0vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mjafi.2020.08.004_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005389","article-title":"Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted","volume":"11","author":"Nguyen","year":"2017","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.mjafi.2020.08.004_bib15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in\u00a0vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.mjafi.2020.08.004_bib16","series-title":"Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial","author":"Chen","year":"2020"},{"key":"10.1016\/j.mjafi.2020.08.004_bib17","series-title":"Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study","author":"Cai","year":"2020"},{"key":"10.1016\/j.mjafi.2020.08.004_bib18","author":"James Ives"},{"key":"10.1016\/j.mjafi.2020.08.004_bib19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s13054-020-03078-z","article-title":"Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series","volume":"24","author":"Doi","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.mjafi.2020.08.004_bib23","unstructured":"Personal Communication.."},{"key":"10.1016\/j.mjafi.2020.08.004_bib24","series-title":"Report on the Deliberation Results \u2013 Avigan. Japan","author":"Pharmaceuticals and Medical Devices Agency","year":"2011"},{"key":"10.1016\/j.mjafi.2020.08.004_bib25","doi-asserted-by":"crossref","DOI":"10.5414\/CP202388","article-title":"Lack of effect of favipiravir, a novel antiviral agent, on the QT interval in healthy Japanese adults","volume":"53","author":"Kumagai","year":"2015","journal-title":"Int J Clin Pharm Ther"},{"key":"10.1016\/j.mjafi.2020.08.004_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2055-6640(20)30016-9","article-title":"A review of the safety of favipiravir \u2013 a potential treatment in the COVID-19 pandemic?","volume":"6","author":"Pilkington","year":"2020","journal-title":"J Virus Erad"},{"key":"10.1016\/j.mjafi.2020.08.004_bib27","series-title":"Favipiravir and Remdesivir Appear to Be Relatively Unencumbered with Drug-Drug Interactions - Anesthesia Patient Safety Foundation","author":"Catherine","year":"2020"},{"key":"10.1016\/j.mjafi.2020.08.004_bib28","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 - preliminary report","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mjafi.2020.08.004_bib29","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mjafi.2020.08.004_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20420","article-title":"Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data","volume":"20","author":"Heneghan","year":"2016","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.mjafi.2020.08.004_bib31","series-title":"Appili Set to Evaluate Favipiravir as Preventive Measure against Covid-19","year":"2020"},{"key":"10.1016\/j.mjafi.2020.08.004_bib32","series-title":"Glenmark Starts Phase III Favipiravir Combination Trial for Covid-19","author":"Tirumalaraju","year":"2020"}],"container-title":["Medical Journal Armed Forces India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0377123720301581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0377123720301581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:48:50Z","timestamp":1759837730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0377123720301581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0377123720301581"],"URL":"https:\/\/doi.org\/10.1016\/j.mjafi.2020.08.004","relation":{},"ISSN":["0377-1237"],"issn-type":[{"value":"0377-1237","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Favipiravir: A new and emerging antiviral option in COVID-19","name":"articletitle","label":"Article Title"},{"value":"Medical Journal Armed Forces India","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mjafi.2020.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}